VEGFA and age-related macular degeneration: An aptamer currently in clinical use is pegaptanib, an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165, responsible for pathological ocular neovascularization associated with age-related macular degeneration (Ng et al., 2006).